(Q37886661)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21654742%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

review article

1 reference

title

New drug targets for the treatment of obesity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21654742%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21654742%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

A G Powell

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21654742%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

L J Aronne

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21654742%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

English

0 references

publication date

8 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21654742%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21654742%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

90

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21654742%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21654742%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

40-51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21654742%20AND%20SRC:MED&resulttype=core&format=json

Actual Causes of Death in the United States, 2000

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Current estimates of the economic cost of obesity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Long-term effects of modest weight loss in type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Pharmacologic treatment options for obesity: current and potential medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Rational design of a combination medication for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Anatomy and regulation of the central melanocortin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Diet-induced obese mice develop peripheral, but not central, resistance to leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Pancreatic amylin as a centrally acting satiating hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Amylinergic control of food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Pharmacological treatment of the overweight patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Our journey with neuropeptide Y: effects on ingestive behaviors and energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Inhibition of food intake in obese subjects by peptide YY3-36

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Overexpression of Agrt leads to obesity in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

A TRbeta-selective agonist confers resistance to diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

Crossing the hurdles of thyroid hormone receptor-α activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

21 January 2018

Health risks of obesity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82

inferred from DOI database lookup

7 January 2021

based on heuristic

Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.82